M-Life’s™ Molecular Systems Approach Enables Understanding of Efficacy and Toxicity Origins at the Atomic Level Leading to the Next Generation for Drug Discovery
NASHVILLE, TENNESSEE – M-LIFE™ announced the successful conclusion of IL-6 molecular systems milestone pursuant to the advancement of a new generation of drugs. The milestone represents M-Life’s ability to decouple efficacy and toxicity and paves the way for new classes of Interleukin six (IL-6) inhibitors which aligns with the Company’s pursuit of offering better drugs for the treatment of chronic, quality of life conditions like Rheumatoid Arthritis (RA), Lupus, Crohn’s Disease and others.